CRISPR Firm Intellia Prices IPO at $16 to $18 Per Share

Apr 27, 2016

|

NEW YORK (GenomeWeb) – Intellia Therapeutics has priced shares for its upcoming initial public offering in the range of $16 to $18, according to an amendment to its preliminary prospectus filed today with the US Securities and Exchange Commission.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Featured White Papers

Can Saliva Replace Blood for DNA Collection and Analysis?

Best Practices for RNA Transcriptome Sequencing

Tissue Section Imaging

In Vivo Validation of Optical Probes

Aug

07

Featured Webinar

Rapid and Comprehensive NGS Variant Interpretation Using Web-Based Software

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

Main menu